TYRA BIOSCIENCES, INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2018-01-01
- Employees
- 49
- Market Cap
- $1.1B
- Website
- http://www.tyra.bio
- Introduction
Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. Its proprietary in-house discovery platform, SN?P, enables the rapid and precise refinement of structural design through iterative molecular SN?Pshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA is developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor (FGFR) family members, which are altered in approximately 7% of all cancers. The company was founded by Daniel Bensen and Todd Harris on August 2, 2018 and is headquartered in Carlsbad, CA.
Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations
- Conditions
- Locally Advanced CholangiocarcinomaIntrahepatic CholangiocarcinomaSolid TumorMetastatic Cholangiocarcinoma
- Interventions
- Drug: Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cyclesDrug: Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cycles
- First Posted Date
- 2023-12-07
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Tyra Biosciences, Inc
- Target Recruit Count
- 40
- Registration Number
- NCT06160752
- Locations
- 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸The Ohio State University, Columbus, Ohio, United States
A Relative Bioavailability and Food Effect Study of TYRA-300-B01 Capsule and Tablet Formulations in Healthy Adult Participants
- Conditions
- Healthy
- Interventions
- Drug: TYRA-300-B01
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2024-03-25
- Lead Sponsor
- Tyra Biosciences, Inc
- Target Recruit Count
- 60
- Registration Number
- NCT06006702
- Locations
- 🇦🇺
Nucleus Network, Melbourne, Victoria, Australia
Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations
- Conditions
- Urothelial CarcinomaSolid Tumor, AdultNon-muscle-invasive Bladder CancerAdvanced Urothelial CarcinomaLocally Advanced Urothelial CarcinomaMetastatic Urothelial CarcinomaAdvanced Solid TumorSolid TumorUrinary Tract CancerUrinary Tract Tumor
- Interventions
- Drug: TYRA-300
- First Posted Date
- 2022-09-16
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Tyra Biosciences, Inc
- Target Recruit Count
- 310
- Registration Number
- NCT05544552
- Locations
- 🇺🇸
Cleveland Clinic - Main Campus, Cleveland, Ohio, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸UMass Memorial Medical Center, Worcester, Massachusetts, United States